Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon ...
Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients ...
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...
On June 6, the U.S. Food and Drug Administration (FDA) approved Geron's first drug, imetelstat (brand name Rytelo), to treat ...
The new weight-loss drug company emerged from stealth with big plans to take on obesity drugs like Wegovy and Zepbound.
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European ...
The lucrative obesity market is projected to hit $130B by 2030, with Eli Lilly and Novo Nordisk leading the charge. Amgen is ...
President Joe Biden and former President Donald Trump have seemingly found one issue they can agree on: Drug costs are too high. Each is crediting himself with price-busting policy successes that ...